Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.
D000368:Aged; D000069059:Atorvastatin; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000191:economics* / Q000628:therapy; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage* / Q000191:economics*; D017721:Hospital Costs; D006760:Hospitalization / Q000191:economics; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000191:economics*; D008297:Male; D006278:Medicare / Q000191:economics; D008875:Middle Aged; D009204:Myocardial Revascularization / Q000191:economics / Q000706:statistics & numerical data; D017063:Outcome Assessment, Health Care; D011446:Prospective Studies; D011758:Pyrroles / Q000008:administration & dosage* / Q000191:economics*; D014481:United States
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin